Skip to content

R&D at other companies

Abbott logo
AbbottABT
$767M+7.1%
Haemonetics logo
HaemoneticsHAE
$14.45M-21.1%
Medtronic logo
MedtronicMDT
$671M-1.9%
ITG
Integer HoldingsITGR
$16.24M+14.4%
Stryker logo
StrykerSYK
$413M+2.0%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$22.61M+0.6%

Segments

By segment

See full
Neuromodulation$40.79M+59.5%
Cardiopulmonary$17.8M+47.7%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's R&D?
LivaNova (LIVN) reported R&D of $58.7M in Q1 2026.
How has LivaNova's R&D changed year-over-year?
LivaNova's R&D increased by 55.0% year-over-year, from $37.88M to $58.7M.
What is the long-term trend for LivaNova's R&D?
Over 4 years (2021 to 2025), LivaNova's R&D has grown at a 0.3% compound annual growth rate (CAGR), from $183.41M to $185.76M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.